Walter H. Moos became CEO of ShangPharma Innovation in 2017, and has been an adjunct Prof. at the University of California San Francisco since 1992. In 2016 he retired from his position as President of SRI Biosciences (Stanford Research Institute). Previously he was Chairman/CEO of MitoKor (Migenix) and a Vice President at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer). Moos and his teams have made significant contributions to all phases of R&D, from early-stage research on therapeutics and diagnostics to marketed pharmaceutical products, supported by biotechnology and pharmaceutical companies, foundations, government agencies, and venture capital. Moos has also served on about 20 business and scientific boards, not-for-profit and for-profit, including the Biotechnology Industry Organization (BIO), Circle, the Critical Path Institute, Keystone Symposia, Oncologic (Aduro), Onyx (Amgen), and Rigel. He has advised and served as a committee member for academic, government, and investor groups, including the University of Michigan, the U.S. National Academy of Sciences, and Red Abbey Venture Partners. He has co-founded several scientific journals, co-authored or co-edited 6 books, and has over 160 patents and publications. Moos received A.B. and Ph.D. degrees in chemistry from Harvard and UC Berkeley.